# Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

> **NCT03212521** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 230 (actual)

## Conditions studied

- Hepatitis C Virus (HCV)

## Interventions

- **DRUG:** Glecaprevir/Pibrentasvir

## Key facts

- **NCT ID:** NCT03212521
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-07
- **Primary completion:** 2018-08-13
- **Final completion:** 2018-08-13
- **Target enrollment:** 230 (ACTUAL)
- **Last updated:** 2019-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03212521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03212521, "Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03212521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*